Alzchem Group AG · ISIN: DE000A2YNT30 · EQS - Company News

Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052 - 3rd Interim Report

Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052     Trostberg, December 23rd, 2024     3rd Interim Report   In the period from December 16th up to and including December 20th, 2024, a total of 9,277 shares of Alzchem Group AG were acquired as part of the share buyback programme announced on November 29th, 2024. The total number of shares acquired to date as part of this buyback amounts to 25,578. The acqu...

XETR:ACT Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Alzchem Group AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (6)
Short Selling (DE) (0)
Short Selling (UK) (0)
23 December 2024 02:32PM
Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052 - 3rd Interim Report
DE000A2YNT30
Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052     Trostberg, December 23rd, 2024     3rd Interim Report   In the period from December 16th up to and including December 20th, 2024, a total of 9,277 shares of Alzchem Group AG were acquired as part of the sha...
Alzchem Group AG
About the publication
17 December 2024 11:45AM
 Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052, Temporary Interruption of Share Repurchase Program
DE000A2YNT30
Alzchem Group AG    Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052   Temporary Interruption of Share Repurchase Program     Alzchem Group AG temporarily interrupts its share repurchase program as published by announcement dated November 29, 2024 starting ...
Alzchem Group AG
About the publication
16 December 2024 12:05PM
Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052 - 2nd Interim Report
DE000A2YNT30
Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052     Trostberg, December 16th, 2024     2nd Interim Report   In the period from December 9th up to and including December 13th, 2024, a total of 13.964  shares of Alzchem Group AG were acquired as part of the sh...
Alzchem Group AG
About the publication
11 December 2024 08:45AM
Private placement of Alzchem shares by LIVIA Corporate Development SE and HDI Vier CE GmbH successfully completed
DE000A2YNT30
Alzchem Group AG: Private placement of Alzchem shares by LIVIA Corporate Development SE and HDI Vier CE GmbH successfully completed Trostberg, December 11, 2024 – Alzchem Group AG has been informed by its shareholders, LIVIA Corporate Development SE und HDI Vier CE GmbH, that the announced private placement of 250,000 shares (representing approxim...
Alzchem Group AG
About the publication
10 December 2024 05:35PM
LIVIA Corporate Development SE and HDI Vier CE GmbH inform about intended private placement of in total up to 250.000 Alzchem Group AG shares
DE000A2YNT30
Alzchem Group AG: LIVIA Corporate Development SE and HDI Vier CE GmbH inform about intended private placement of in total up to 250.000 Alzchem Group AG shares Trostberg, December 10, 2024 – LIVIA Corporate Development SE and HDI Vier CE GmbH have informed Alzchem Group AG (ISIN DE000A2YNT30, WKN A2YNT3, Prime Standard) today that they intend to s...
Alzchem Group AG
About the publication
09 December 2024 01:45PM
Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052 - 1st Interim Report
DE000A2YNT30
Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052     Trostberg, December 9th, 2024     1st Interim Report   In the period from December 2nd up to and including December 6th, 2024, a total of 2,337 shares of Alzchem Group AG were acquired as part of the share ...
Alzchem Group AG
About the publication
04 December 2024 06:13PM
Supervisory Board appoints Martina Spitzer as Chief Sales Officer effective January 1, 2025
DE000A2YNT30
Alzchem Group AG implements long-term succession planning for Management Board: Supervisory Board appoints Martina Spitzer as Chief Sales Officer effective January 1, 2025 Trostberg, December 4, 2024 – Alzchem Group AG, a globally active specialty chemicals company, is setting the course for continuous and sustainably successful development in Man...
Alzchem Group AG
About the publication
29 November 2024 03:32PM
Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052 - Share Repurchase
DE000A2YNT30
      Alzchem Group AG    Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052   Share Repurchase     Alzchem Group AG announces the start of the share repurchase program which was published by an ad hoc announcement dated November 5, 2024.   Starting Dece...
Alzchem Group AG
About the publication
12 November 2024 09:04AM
Alzchem Group new partner of FC Bayern Basketball
DE000A2YNT30
EQS-Media / 12.11.2024 / 09:04 CET/CEST Alzchem Group new partner of FC Bayern Basketball Munich, November 12, 2024 – FC Bayern Basketball and Alzchem, a company based in Trostberg, have joined forces for the new season to achieve success together. With Alzchem's premium brand Creapure®, the internationally renowned manufacturer of creatine m...
Alzchem Group AG
About the publication
07 November 2024 06:55AM
Alzchem Group AG reports 36.4% EBITDA growth to EUR 76.8 million – strong earnings performance continues in the first nine months of 2024
DE000A2YNT30
Alzchem Group AG reports 36.4% EBITDA growth to EUR 76.8 million – strong earnings performance continues in the first nine months of 2024 Trostberg, November 7, 2024 – Alzchem Group AG, a globally active specialty chemicals company, continues its consistent transformation towards higher-margin specialty chemicals and was able to significantly incr...
Alzchem Group AG
About the publication
05 November 2024 02:42PM
Alzchem Group AG resolves to buy back shares for up to EUR 6 million
DE000A2YNT30
Trostberg, November 5, 2024 – The Management Board of Alzchem Group AG has resolved, with the approval of the Supervisory Board, to buy back up to 100.000 shares in the company via the stock exchange for a total purchase price of up to EUR 6 million (excluding transaction costs) over a period of up to 12 months from December 2024. The buyback is f...
Alzchem Group AG
About the publication
24 October 2024 10:35AM
Alzchem Group AG supports grid stability through flexible load control
DE000A2YNT30
Provision of balancing energy: Alzchem Group AG supports grid stability through flexible load control Trostberg, October 24, 2024 – Alzchem Group AG, a globally active specialty chemicals company, makes a significant contribution to the stability of the power grid with its two carbide furnaces at the Hart site. The electrical output of both furnac...
Alzchem Group AG
About the publication
02 October 2024 11:06AM
Alzchem Group AG plans to double nitroguanidine production capacity in Germany
DE000A2YNT30
Alzchem Group AG plans to double nitroguanidine production capacity in Germany Trostberg, October 2, 2024 – Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, plans to significantly increase its production capacity for nitroguanidine. It was only in spring of this year t...
Alzchem Group AG
About the publication
02 October 2024 11:00AM
Doubling of nitroguanidine production capacities planned in Germany; preliminary contract for site search in the USA concluded
DE000A2YNT30
Trostberg, October 2, 2024 – Alzchem Group AG plans significantly increase its production capacity for nitroguanidine. It was only in spring of this year that the company announced a capacity expansion for the preliminary stage with an investment of EUR 76 million over several years. Taking into account the additional expansion plans for a new prod...
Alzchem Group AG
About the publication
01 October 2024 03:52PM
Alzchem Group AG set to join the SDAX on October 2, 2024
DE000A2YNT30
Alzchem Group AG set to join the SDAX on October 2, 2024 Trostberg, October 1, 2024 – Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, will be included in the SDAX selection index for the first time on October 2, 2024. This makes Alzchem one of the 160 largest and most...
Alzchem Group AG
About the publication
01 August 2024 07:00AM
Continued strong growth in Specialty Chemicals business leads to significant EBITDA increase of 41.2% to EUR 51.9 million in the first half of 2024
DE000A2YNT30
Alzchem Group AG: Continued strong growth in Specialty Chemicals business leads to significant EBITDA increase of 41.2% to EUR 51.9 million in the first half of 2024  Half-year result climbs by 78.4% to EUR 26.7 million Free cash flow increases by 64.5% to EUR 51.4 million Management Board raises earnings forecasts for the full year 2024 Trostbe...
Alzchem Group AG
About the publication
30 July 2024 09:21AM
Alzchem Group AG raises forecasts for EBITDA and EBITDA margin in fiscal year 2024
DE000A2YNT30
Alzchem Group AG raises forecasts for EBITDA and EBITDA margin in fiscal year 2024 Trostberg, July 30, 2024 – Alzchem Group AG is raising its earnings forecasts for fiscal year 2024. Group EBITDA will grow to over EUR 100 million with unchanged sales expectations (original forecast: approx. EUR 90 million). The raise in the EBITDA forecast leads t...
Alzchem Group AG
About the publication
07 June 2024 03:15PM
Three Alzchem climate projects receive public funding of around EUR 850 thousand
DE000A2YNT30
Alzchem Group AG: Three Alzchem climate projects receive public funding of around EUR 850 thousand Trostberg, June 7, 2024 – Alzchem has received funding commitments totaling around EUR 850 thousand, which represent non-repayable investment grants this year. Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading mark...
Alzchem Group AG
About the publication
07 May 2024 04:21PM
Alzchem Group AG receives strong support from shareholders at Annual General Meeting; dividend increase to EUR 1.20 per share approved
DE000A2YNT30
Alzchem Group AG receives strong support from shareholders at Annual General Meeting; dividend increase to EUR 1.20 per share approved Trostberg, May 7, 2024 – At today’s virtual Annual General Meeting, the Management Board and Supervisory Board once again received strong approval from the shareholders of Alzchem Group AG for their direction of th...
Alzchem Group AG
About the publication
07 May 2024 04:21PM
Alzchem Group AG receives strong support from shareholders at Annual General Meeting; dividend increase to EUR 1.20 per share approved
DE000A2YNT30
Alzchem Group AG receives strong support from shareholders at Annual General Meeting; dividend increase to EUR 1.20 per share approved Trostberg, May 7, 2024 – At today’s virtual Annual General Meeting, the Management Board and Supervisory Board once again received strong approval from the shareholders of Alzchem Group AG for their direction of th...
Alzchem Group AG
About the publication
30 April 2024 07:00AM
Alzchem Group AG seamlessly builds on strong business performance in 2023 with EBITDA growth of 31.7% in first quarter 2024
DE000A2YNT30
Alzchem Group AG seamlessly builds on strong business performance in 2023 with EBITDA growth of 31.7% in first quarter 2024 Result for the period increases significantly by 58.7% to EUR 12.2 million Strong free cash flow of EUR 26.6 million Management Board confirms forecasts for the full year 2024 Trostberg, April 30, 2024 – Alzchem Group AG, a...
Alzchem Group AG
About the publication
15 March 2024 05:56PM
Alzchem Group AG receives EUR 34.4 million in EU funding
DE000A2YNT30
Trostberg, 15 March 2024 - Following a Europe-wide selection process, Alzchem Group AG has been awarded an investment grant of EUR 34.4 million by the EU Commission as part of the ASAP ("Act in Support of Ammunition Production") funding instrument. Alzchem Group AG wants to use the funds over an investment period of two and a half years to increase...
Alzchem Group AG
About the publication
11 March 2024 11:15AM
Successful addition of creatine to dialysis patient treatments
DE000A2YNT30
EQS-Media / 11.03.2024 / 11:15 CET/CEST Crearene AG and Alzchem Group AG: Successful addition of creatine to dialysis patient treatments As part of their cooperation, Alzchem Group AG and Crearene AG announced in October 2023 that a clinical study on the use of creatine in dialysis treatments had been launched. The aim is to demonstrate the t...
Alzchem Group AG
About the publication
01 March 2024 07:00AM
EBITDA increase of 32.4 % to EUR 81.4 million – continuing on the road to success
DE000A2YNT30
Alzchem Group AG: EBITDA increase of 32.4 % to EUR 81.4 million – continuing on the road to success High-growth specialty chemicals business proves to be a key earnings driver and important sales pillar Dividend increase to EUR 1.20 planned Forecast for 2024 envisages rise in sales and EBITDA Trostberg, March 1, 2024 – Alzchem Group AG, a verti...
Alzchem Group AG
About the publication
11 January 2024 03:28PM
New clinical studies show high efficacy of creatine supplementation
DE000A2YNT30
EQS-Media / 11.01.2024 / 15:28 CET/CEST Long-Covid: New clinical studies show high efficacy of creatine supplementation  Creatine is a natural, endogenous substance that plays a central role as an energy transporter and buffer in every cell. It is an essential component of cellular energy metabolism and is therefore important for all energy-i...
Alzchem Group AG
About the publication
13 December 2023 02:09PM
Outstanding result certified by 'Together for Sustainability (TfS)' initiative
DE000A2YNT30
EQS-Media / 13.12.2023 / 14:09 CET/CEST Alzchem awarded for sustainable supply chains: Outstanding result certified by "Together for Sustainability (TfS)" initiative With 192 out of a possible 200 points, Alzchem ranks very high in the audit of the industry initiative "Together for Sustainability (TfS)". This certifies that the specialty chem...
Alzchem Group AG
About the publication
08 December 2023 11:12AM
Supervisory Board appoints Andreas Lösler as new CFO with effect from 1 January 2024
DE000A2YNT30
Alzchem Group AG expands Management Board: Supervisory Board appoints Andreas Lösler as new CFO with effect from 1 January 2024 Trostberg, December 8, 2023 – Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, is expanding its Management Board team. At its meeting on 5 De...
Alzchem Group AG
About the publication
26 October 2023 06:55AM
Alzchem Group AG significantly increases EBITDA by 19.8% to EUR 56.3 million in the nine-month period 2023
DE000A2YNT30
Alzchem Group AG significantly increases EBITDA by 19.8% to EUR 56.3 million in the nine-month period 2023 Sales growth in Specialty Chemicals segment supports increased EBITDA margin of 14.2% Free cash flow rises significantly to EUR 30.5 million Adjusted forecast 2023: Strong EBITDA growth to approx. EUR 80 million, sales stable at previous ye...
Alzchem Group AG
About the publication
18 October 2023 04:23PM
Alzchem Group AG raises EBITDA forecast into the range of EUR 80 million for fiscal year 2023 despite slightly lower sales expectation
DE000A2YNT30
Alzchem Group AG is significantly raising its earnings forecast for the fiscal year 2023 despite a slightly lower sales expectation. Group EBITDA is expected to grow to approximately EUR 80 million (original forecast: up to EUR 70 million). Group sales are expected to be at or slightly below the previous year’s level of EUR 542.2 million; this is s...
Alzchem Group AG
About the publication
14 September 2023 11:08AM
Wholesome taste and positive benefits for vegetarian and vegan foods
DE000A2YNT30
EQS-Media / 14.09.2023 / 11:08 CET/CEST Creatine product "Creavitalis": Wholesome taste and positive benefits for vegetarian and vegan foods   Meat substitutes are very much in vogue. Burgers, bratwurst, cold cuts - there is hardly a product for which there is not now a meat-free variant. Manufacturers of plant-based alt...
Alzchem Group AG
About the publication
03 August 2023 07:00AM
Alzchem Group AG reports positive business development in the first half of 2023
DE000A2YNT30
Alzchem Group AG reports positive business development in the first half of 2023 Sales increase by 3% to EUR 277.0 million EBITDA grows by 5% to EUR 36.8 million Strong free cash flow of EUR 31.3 million Forecast confirmed: for the full year, sales expected to be at the lower end of the range, EBITDA at the upper end of the range Trostberg, Au...
Alzchem Group AG
About the publication
03 August 2023 07:00AM
Alzchem Group AG reports positive business development in the first half of 2023
DE000A2YNT30
Alzchem Group AG reports positive business development in the first half of 2023 Sales increase by 3% to EUR 277.0 million EBITDA grows by 5% to EUR 36.8 million Strong free cash flow of EUR 31.3 million Forecast confirmed: for the full year, sales expected to be at the lower end of the range, EBITDA at the upper end of the range Trostberg, Au...
Alzchem Group AG
About the publication
12 May 2023 09:04AM
Alzchem Group AG ensures continuity on the Management Board: Contract extension with CEO Andreas Niedermaier until 2026
DE000A2YNT30
Alzchem Group AG ensures continuity on the Management Board: Contract extension with CEO Andreas Niedermaier until 2026 Trostberg, 12 Mai 2023 – The Supervisory Board of Alzchem Group AG has extended early the service contract of Chief Executive Officer Andreas Niedermaier, which runs until 31 December 2023, by 3 years until 2026. The vertically i...
Alzchem Group AG
About the publication
12 May 2023 09:04AM
Contract extension with CEO Andreas Niedermaier until 2026
DE000A2YNT30
Alzchem Group AG ensures continuity on the Management Board: Contract extension with CEO Andreas Niedermaier until 2026 Trostberg, 12 Mai 2023 – The Supervisory Board of Alzchem Group AG has extended early the service contract of Chief Executive Officer Andreas Niedermaier, which runs until 31 December 2023, by 3 years until 2026. The vertically i...
Alzchem Group AG
About the publication
11 May 2023 04:53PM
Alzchem Group AG: Annual General Meeting resolves increased dividend of EUR 1.05 per share – broad approval of all agenda items, including the climate roadmap
DE000A2YNT30
Alzchem Group AG: Annual General Meeting resolves increased dividend of EUR 1.05 per share – broad approval of all agenda items, including the climate roadmap Trostberg, May 11, 2023 – The shareholders of Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, approved all it...
Alzchem Group AG
About the publication
11 May 2023 04:53PM
Annual General Meeting resolves increased dividend of EUR 1.05 per share – broad approval of all agenda items, including the climate roadmap
DE000A2YNT30
Alzchem Group AG: Annual General Meeting resolves increased dividend of EUR 1.05 per share – broad approval of all agenda items, including the climate roadmap Trostberg, May 11, 2023 – The shareholders of Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, approved all it...
Alzchem Group AG
About the publication
04 May 2023 06:55AM
Alzchem Group AG achieves significant sales and earnings growth in the first quarter of 2023
DE000A2YNT30
Alzchem Group AG achieves significant sales and earnings growth in the first quarter of 2023 Sales increase by 16% to EUR 150.4 million EBITDA rises by 11% to EUR 18.9 million Operating cash flow and free cash flow positive again Outlook 2023 confirmed Trostberg, May 4, 2023 – Alzchem Group AG, a vertically integrated specialty chemicals suppl...
Alzchem Group AG
About the publication
04 May 2023 06:55AM
Alzchem Group AG achieves significant sales and earnings growth in the first quarter of 2023
DE000A2YNT30
Alzchem Group AG achieves significant sales and earnings growth in the first quarter of 2023 Sales increase by 16% to EUR 150.4 million EBITDA rises by 11% to EUR 18.9 million Operating cash flow and free cash flow positive again Outlook 2023 confirmed Trostberg, May 4, 2023 – Alzchem Group AG, a vertically integrated specialty chemicals suppl...
Alzchem Group AG
About the publication
28 February 2023 07:00AM
Alzchem Group AG: Alzchem Group AG achieves highest sales in the company’s history in the fiscal year 2022 with EUR 542.2 million (+28.4%)
DE000A2YNT30
Alzchem Group AG achieves highest sales in the company’s history in the fiscal year 2022 with EUR 542.2 million (+28.4%) EBITDA stable at previous year’s level at EUR 61.4 million Annual result increases by 8.9% to EUR 30.2 million Dividend to be raised to EUR 1.05 per share Further sales and EBITDA growth forecast for 2023 Trostberg, February ...
Alzchem Group AG
About the publication
28 February 2023 07:00AM
Alzchem Group AG achieves highest sales in the company’s history in the fiscal year 2022 with EUR 542.2 million (+28.4%)
DE000A2YNT30
Alzchem Group AG achieves highest sales in the company’s history in the fiscal year 2022 with EUR 542.2 million (+28.4%) EBITDA stable at previous year’s level at EUR 61.4 million Annual result increases by 8.9% to EUR 30.2 million Dividend to be raised to EUR 1.05 per share Further sales and EBITDA growth forecast for 2023 Trostberg, February ...
Alzchem Group AG
About the publication
26 October 2022 07:00AM
Alzchem Group AG with strong sales growth of 31.4% in the 9-month period 2022
DE000A2YNT30
Alzchem Group AG with strong sales growth of 31.4% in the 9-month period 2022 EBITDA of EUR 47.0 million at around the previous year’s level Result for the period +6.7% and earnings per share +7.0% Growth and investment course to be continued Forecast for 2022 confirmed Trostberg, October 26, 2022 – Alzchem Group AG, a vertically integrated spe...
Alzchem Group AG
About the publication
26 October 2022 07:00AM
Alzchem Group AG with strong sales growth of 31.4% in the 9-month period 2022
DE000A2YNT30
Alzchem Group AG with strong sales growth of 31.4% in the 9-month period 2022 EBITDA of EUR 47.0 million at around the previous year’s level Result for the period +6.7% and earnings per share +7.0% Growth and investment course to be continued Forecast for 2022 confirmed Trostberg, October 26, 2022 – Alzchem Group AG, a vertically integrated spe...
Alzchem Group AG
About the publication
31 August 2022 02:23PM
Alzchem and Crearene Develop Treatments for the Dialysis Market
DE000A2YNT30
DGAP-Media / 31.08.2022 / 14:23 CET/CEST Joint Press Release Alzchem and Crearene Alzchem Group AG and Crearene AG, based in Frauenfeld in Switzerland, have agreed on an exclusive memo of understanding (MOU) for the development and commercialization of Creapure®/creatine-based treatment solutions in dialysis. Dialysis is a treatment method w...
Alzchem Group AG
About the publication
31 August 2022 02:23PM
Alzchem and Crearene Develop Treatments for the Dialysis Market
DE000A2YNT30
DGAP-Media / 31.08.2022 / 14:23 CET/CEST Joint Press Release Alzchem and Crearene Alzchem Group AG and Crearene AG, based in Frauenfeld in Switzerland, have agreed on an exclusive memo of understanding (MOU) for the development and commercialization of Creapure®/creatine-based treatment solutions in dialysis. Dialysis is a treatment method w...
Alzchem Group AG
About the publication
26 July 2022 07:00AM
Alzchem Group AG increases sales by 25.3% in the first half of 2022
DE000A2YNT30
Sales growth to EUR 269.8 million mainly due to price effects EBITDA of EUR 34.9 million almost at previous year’s level Result for the period slightly higher at EUR 17.4 million Equity ratio up from 23.7% to 30.9% Increased sales forecast for fiscal year 2022 confirmed Trostberg, 26 July 2022 – Alzchem Group AG, a vertically integrated specia...
Alzchem Group AG
About the publication
26 July 2022 07:00AM
Alzchem Group AG increases sales by 25.3% in the first half of 2022
DE000A2YNT30
Sales growth to EUR 269.8 million mainly due to price effects EBITDA of EUR 34.9 million almost at previous year’s level Result for the period slightly higher at EUR 17.4 million Equity ratio up from 23.7% to 30.9% Increased sales forecast for fiscal year 2022 confirmed Trostberg, 26 July 2022 – Alzchem Group AG, a vertically integrated specia...
Alzchem Group AG
About the publication
05 May 2022 04:09PM
Annual General Meeting 2022 of Alzchem Group AG: Broad shareholder approval for growth course and dividend increase
DE000A2YNT30
Annual General Meeting 2022 of Alzchem Group AG: Broad shareholder approval for growth course and dividend increaseTrostberg, 5 May 2022 – Today’s virtual Annual General Meeting of Alzchem Group AG expressed its continued confidence in the Management Board and the Supervisory Board by discharging them for the fiscal year 2021 and approved all agend...
Alzchem Group AG
About the publication
02 May 2022 12:00PM
Alzchem Group AG: Early contract extension with CSO Dr. Georg Weichselbaumer and COO Klaus Englmaier
DE000A2YNT30
Early contract extension with CSO Dr. Georg Weichselbaumer and COO Klaus Englmaier Trostberg, 2 May 2022 - The Supervisory Board of Alzchem Group AG has extended the Management Board contracts of Dr. Georg Weichselbaumer (CSO) and Klaus Englmaier (COO) ahead of schedule until the end of 2025. Markus Zöllner, Chairman of the Supervisory Board: "Wit...
Alzchem Group AG
About the publication
More Alzchem Group AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 6 15th November 2024 Weichselbaumer, Dr. Georg DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN